The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

Sickle cell disease is a severe, inherited blood disorder that primarily affects people of African, Mediterranean, Middle ...

Vertex Pharma has teamed up with Orum Therapeutics ... patients undergo myeloablative chemo to wipe out their bone marrow, removing unhealthy blood stem cells and making room for the new, edited ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first in the Middle East to approve Casgevy for the treatment of SCD and TDT. The ...

In 2024, BOC received Vertex accreditation for its bone marrow transplant and cellular therapy services, enabling it to provide, as an accredited centre of excellence, CRISPR-based gene-editing ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Sickle-cell disease can be treated by a bone-marrow transplant containing stem ... but at current prices Vertex believes Casgevy to be a multibillion-dollar prospect. Analysts agree, citing ...

cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy that involves harvesting bone marrow stem cells from patients ...

MANAMA, Feb. 16 (Xinhua) -- Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using CRISPR-based gene-editing therapy, Casgevy, the Bahrain ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

One day, we must all leave this world without regret. It may not happen when we expect it, but no one is exempt.